Analysis weighs benefits, adverse effects of RLS drugs

05/12/2008 | Forbes

A meta-analysis of 14 trials involving four nonergot dopamine agonists -- first-line treatments for restless legs syndrome -- found that the drug ropinerole appeared to cause the "most profound side effects," leading patients to stop therapy. The American College of Neurology will release guidelines on the use of NEDA medicines by the end of the year, an expert said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA